IRIS
PUXEDDU, ERMANNO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.097
AS - Asia 1.942
EU - Europa 1.710
SA - Sud America 268
AF - Africa 28
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 8
Totale 18.063
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.034
SG - Singapore 839
IT - Italia 345
CN - Cina 328
KR - Corea 240
FR - Francia 229
BR - Brasile 220
DE - Germania 212
RU - Federazione Russa 199
HK - Hong Kong 162
IE - Irlanda 161
VN - Vietnam 158
UA - Ucraina 143
PL - Polonia 129
GB - Regno Unito 107
SE - Svezia 51
IN - India 49
JP - Giappone 47
FI - Finlandia 43
CA - Canada 34
NL - Olanda 27
MX - Messico 20
AR - Argentina 18
BE - Belgio 16
BD - Bangladesh 12
ES - Italia 11
ID - Indonesia 11
MY - Malesia 11
TW - Taiwan 11
AU - Australia 9
IQ - Iraq 9
TR - Turchia 9
RO - Romania 8
CL - Cile 7
EC - Ecuador 7
KG - Kirghizistan 7
PK - Pakistan 7
SA - Arabia Saudita 7
AT - Austria 6
EG - Egitto 6
JM - Giamaica 6
EU - Europa 5
ZA - Sudafrica 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
HU - Ungheria 4
MA - Marocco 4
NG - Nigeria 4
PE - Perù 4
PY - Paraguay 4
TH - Thailandia 4
UZ - Uzbekistan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
GR - Grecia 3
IL - Israele 3
PH - Filippine 3
RS - Serbia 3
VE - Venezuela 3
BH - Bahrain 2
CH - Svizzera 2
CR - Costa Rica 2
GA - Gabon 2
IR - Iran 2
JO - Giordania 2
LB - Libano 2
LT - Lituania 2
LY - Libia 2
SY - Repubblica araba siriana 2
AM - Armenia 1
AZ - Azerbaigian 1
BW - Botswana 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
GN - Guinea 1
KE - Kenya 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
NP - Nepal 1
NR - Nauru 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TN - Tunisia 1
Totale 18.063
Salva come PNG Salva come JPEG
Città #
Woodbridge 3.479
Wilmington 3.462
Houston 3.407
Fairfield 500
Singapore 467
Ann Arbor 321
Chandler 288
Ashburn 276
Seattle 219
San Jose 195
Cambridge 170
Hong Kong 158
Beijing 144
Dublin 128
Kraków 119
Medford 104
Jacksonville 103
Rome 86
New York 82
The Dalles 77
Santa Clara 70
Dearborn 69
Los Angeles 59
Council Bluffs 58
Lawrence 47
Lauterbourg 45
Tokyo 40
Ho Chi Minh City 38
Dallas 36
Menlo Park 32
Moscow 32
Hanoi 31
Redwood City 23
San Diego 23
Buffalo 20
São Paulo 19
Palo Alto 18
Brussels 16
Helsinki 15
Milan 15
Monte Vista 15
Orem 15
Phoenix 15
Naples 14
Chicago 13
Colorado Springs 13
Redondo Beach 13
Chennai 12
Verona 12
Zhengzhou 12
Guangzhou 11
London 11
Nuremberg 11
Rio de Janeiro 11
Seoul 11
Denver 10
Jakarta 10
Nanjing 10
Stockholm 10
Frankfurt am Main 9
Munich 9
Boardman 8
Norwalk 8
Liverpool 7
New Delhi 7
San Francisco 7
Warsaw 7
Wuhan 7
Amsterdam 6
Atlanta 6
Baghdad 6
Brooklyn 6
Istanbul 6
Manchester 6
Mountain View 6
North Bergen 6
Shanghai 6
Belo Horizonte 5
Biberach an der Riss 5
Boston 5
Columbia 5
Columbus 5
Genoa 5
Haiphong 5
Hefei 5
Johannesburg 5
Kingston 5
Kunming 5
Mumbai 5
Mülheim 5
Pescara 5
Santiago 5
Shirwal 5
Surrey 5
Abuja 4
Cairo 4
Charlotte 4
Da Nang 4
Delhi 4
Dong Ket 4
Totale 14.952
Salva come PNG Salva come JPEG
Nome #
Idiopathic Pulmonary Fibrosis (IPF) incidence and prevalence in Italy 788
Interaction between corticosteroids and muscarinic antagonists in human airways 503
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 503
A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD 501
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 479
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 478
Airflow obstruction: Is it asthma or is it COPD? 475
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 473
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 473
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside 470
Optimizing drug delivery in COPD: The role of inhaler devices 460
M. avium binding to HLA-DR expressed alleles in silico: A model of phenotypic susceptibility to sarcoidosis 458
HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis 458
Acute COPD exacerbation: 3 T MRI evaluation of pulmonary regional perfusion--preliminary experience. 455
Metodo per la diagnosi in vitro di fibrosi polmonare/polmonite interstiziale idiopatica e uso di chelanti del ferro per il trattamento della fibrosi polmonare/polmonite interstiziale idiopatica 443
The prevalence of asthma and COPD in Italy: a practice-based study 441
Is allergic sensitization to siberian hamster preventable in high-risk individuals who are already sensitized or exposed to furry animals? 431
Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD 429
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 427
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 426
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 426
Iron laden macrophages in idiopathic pulmonary fibrosis: The telltale of occult alveolar hemorrhage? 420
Reactivity to mycobacterial antigens by patients with Lofgren's syndrome as a model of phenotypic susceptibility to disease and disease progression. 419
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 415
Adherence to COPD treatment: Myth and reality 411
Impact of pulmonary vascular volume on mortality in IPF: Is it time to reconsider the role of vasculature in disease pathogenesis and progression? 408
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis 399
Human embryonic stem cells recover in vivo acute lung inflammation bleomycin-induced 384
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 382
Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine 374
Structured multidisciplinary discussion of HRCT scans for IPF/UIP diagnosis may result in indefinite outcomes 371
Relationship between oxytocin/vasopressin and latex in obstetric surgery: How to recognize (and prevent) allergic reactions and differentiate them from side effects? 369
Dual bronchodilation and exacerbations of COPD 354
Method for in vitro diagnosis of idiopathic pulmonary fibrosis 348
Human embryonic stem cells recover in vivo acute lung inflammation bleomycin-induced 339
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine 247
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 240
Olodaterol + tiotropium bromide for the treatment of COPD 236
Depressive and anxiety symptoms in patients with SARS-CoV2 infection 206
A potential role of triple therapy for asthma patients 185
Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection 179
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations 177
Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers 151
Does bronchoscopy help the diagnosis in COVID-19 infection? 132
CD71- Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease 131
Biomarkers for possible early detection and progression of idiopathic pulmonary fibrosis 131
Dyspnea perception and neurological symptoms in non-severe COVID-19 patients 111
Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review 84
Experimental glucocorticoid receptor agonists for the treatment of asthma: a systematic review 81
Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients 79
Are there pulmonary sequelae in patients recovering from COVID-19? 75
Indacaterol/Glycopyrronium Combination for COPD 70
Bronchoalveolar lavage (BAL) cells in idiopathic pulmonary fibrosis express a complex pro-inflammatory, pro-repair, angiogenic activation pattern, likely associated with macrophage iron accumulation 67
Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review 63
Synergy across the drugs approved for the treatment of asthma 52
Lung involvement in psoriatic arthritis patients: cross-sectional study on prevalence, clinical characteristics, and risk factors of a neglected comorbidity 52
Expert guidance on the management and challenges of long-COVID syndrome: a systematic review 51
Interaction of phosphodiesterase 3A with brefeldin A-inhibited guanine nucleotide-exchange proteins BIG1 and BIG2 and effect on ARF1 activity 33
Interaction of brefeldin A-inhibited guanine nucleotide-exchange protein (BIG) 1 and kinesin motor protein KIF21A 33
Spontaneous Ventilation Thoracoscopic Lung Biopsy in Undetermined Interstitial Lung Disease: Systematic Review and Meta-Analysis 20
null 3
Totale 18.279
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.962
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.962
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021130 0 0 0 0 0 0 0 0 0 0 89 41
2021/2022613 34 56 18 31 25 52 71 28 35 76 52 135
2022/2023691 77 76 22 79 79 144 59 40 58 15 24 18
2023/2024317 46 17 48 9 16 63 18 15 8 16 13 48
2024/20251.365 44 308 135 67 44 92 70 133 143 139 90 100
2025/20262.090 181 131 227 196 206 71 315 251 319 185 8 0
Totale 18.279